ArticleNeuro-oncology advances

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma.

Katja Werlenius et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.